StemCyte International, Ltd. is a biotechnology company specializing in regenerative cell therapy, with a core business centered around umbilical cord blood banking and advanced cellular therapies. Founded in 2013 and headquartered in Taipei, it develops and manufactures innovative cell therapy products, including solutions for both public and private cord blood banking. StemCyte's therapeutic pipeline includes internationally accredited products for allogeneic cell therapies, with ongoing clinical trials for conditions such as long-COVID, acute stroke, and cerebral palsy. Notably, its REGENECYTE cell therapy received U.S. FDA approval, marking a significant milestone in the global cell therapy industry. The company has established one of the largest and most racially diverse public cord blood banks worldwide, supporting more than 2,300 transplants for patients with hematological and immune system diseases. StemCyte collaborates with leading medical institutions across Asia and the United States and maintains rigorous quality standards through certifications such as AABB and FACT. Its market significance lies in pioneering cellular therapy technologies, expanding access to cutting-edge treatments, and driving progress in regenerative medicine within the pharmaceuticals and biotech sector.